6.4.4. role imaging psa-only recurrence. imaging value leads treatment change results improved outcome. practice, however, limited data available regarding outcome’s consequent imaging recurrence. 6.4.4.1. assessment metastases (including nodal) 6.4.4.1.1. bone scan abdominopelvic ct bcr rp rt precedes clinical metastases seven eight years average , diagnostic yield conventional imaging techniques (bone scan abdominopelvic ct) low asymptomatic patients . men psa-only recurrence rp probability positive bone scan < 5%, psa level < 7 ng/ml . 11–14% patients bcr rp positive ct . series 132 men bcr rp mean psa level psa velocity associated positive ct 27.4 ng/ml 1.8 ng/ml/month, respectively . 6.4.4.1.2. choline pet/ct two different meta-analyses combined sensitivities specificities choline pet/ct sites recurrence patients bcr 86–89% 89–93%, respectively . choline pet/ct may detect multiple bone metastases patients showing single metastasis bone scan may positive bone metastases 15% patients bcr rp negative bone scan . specificity choline pet/ct also higher bone scan, fewer false positive indeterminate findings . detection ln metastases using choline pet/ct remains limited relatively poor sensitivity technique (see section 5.3.2.3). choline pet/ct sensitivity strongly dependent psa level kinetics . patients bcr rp, pet/ct detection rates 5–24% psa level < 1 ng/ml rise 67–100% psa level > 5 ng/ml. despite limitations, choline pet/ct may change medical management 18–48% patients bcr primary treatment [915-917]. choline pet/ct recommended patients fit enough curative loco-regional salvage treatment. 6.4.4.1.3. fluoride pet/ct 18f-naf pet/ct higher sensitivity bone scan detecting bone metastases . however, 18f -naf pet/ct limited relative lack specificity fact assess soft-tissue metastases . 6.4.4.1.4. fluciclovine pet/ct 18f-fluciclovine pet/ct approved u.s. europe therefore one pca-specific radiotracers widely commercially available [919-922]. 18f-fluciclovine pet/ct slightly higher sensitivity choline pet/ct detecting site relapse bcr . multi-centre trial evaluating 596 patients bcr mixed population, fluciclovine pet/ct showed overall detection rate 67.7%; lesions could visualised either local level (38.7%) pelvic lns (32.6%) . choline pet/ct, fluciclovine pet/ct sensitivity dependent psa level, sensitivity likely inferior 50% psa level < 1 ng/ml. prospective rct evaluating impact 18f-fluciclovine pet/ct srt management decisions patients recurrence post-prostatectomy, 28 79 (35.4%) patients overall radiotherapeutic management changed following 18f-fluciclovine pet/ct . 18f-fluciclovine pet/ct significantly higher positivity rate conventional imaging (abdominopelvic ct mri plus bone scan) whole body (79.7% vs. 13.9%, p < 0.001), prostate bed (69.6% vs. 5.1%, p < 0.001), pelvic lns (38.0% vs. 10.1%, p < 0.001) . however, yet, data demonstrating changes translate survival benefit available. 6.4.4.1.5. prostate-specific membrane antigen based pet/ct psma pet/ct shown good potential patients bcr, although studies limited retrospective design. reported predictors 68ga-psma pet recurrence setting updated based high-volume series (see table 6.4.2) . high sensitivity (75%) specificity (99%) observed per-lesion analysis. table 6.4.2: psma-positivity separated psa level category psa (ng/ml)68ga-pmsa pet positivity< 0.233% (ci: 16–51)02–0.4945% (ci: 39–52)0.5–0.9959% (ci: 50–68)1.0–1.9975% (ci: 66–84)2.0+95% (ci: 92–97) psa = prostate-specific antigen; 68ga-psma pet = gallium-68 prostate-specific membrane antigen positronemission tomography. psma pet/ct seems substantially sensitive choline pet/ct, especially psa levels < 1 ng/ml . study 314 patients bcr treatment median psa level 0.83 ng/ml, 68ga-psma pet/ct positive 197 patients (67%) . another prospective multi-centre trial including 635 patients bcr rp (41%), rt (27%), (32%), ppv 68ga-psma pet/ct 0.84 (95% ci: 0.75–0.90) histopathologic validation (primary endpoint, n = 87) 0.92 (95% ci: 0.75–0.90) composite reference standard. detection rates significantly increased psa value . prospective multi-centre, multi-reader, open-label, phase ii/iii trial (osprey) evaluated diagnostic performance 18f-dcfpyl patients presumptive radiologic evidence recurrent metastatic pca conventional imaging . median sensitivity median ppv 95.8% (95% ci: 87.8%–99.0%) 81.9% (95% ci: 73.7%–90.2%), respectively. another prospective study evaluated diagnostic performance 18f-dcfpyl 208 men bcr rp rt. primary endpoint, correct localisation rate achieved, demonstrating positive findings 18f-dcfpyl pet/ct setting negative standard conventional imaging . present conclusive data comparison tracers . prospective, open label, cross-over study, python trial, compared per-patient detection rates (dr) 18f-dcfpyl versus 18f-fluoromethylcholine pet/ct, biochemical recurrence (bcr) setting. total 201 high-risk pca patients first bcr radical prostatectomy radiation therapy completed study. per-patient dr significantly higher 18f-dcfpyl compared 18f-fluoromethylcholine pet/ct (58% (117/201 patients) vs. 40% (81/201 patients), p < 0.0001). dr increased higher psa values tracers (psa ≤ 0.5 ng/ml: 26/74 (35%) vs. 22/74 (30%); psa 0.5 ≤ 1.0 ng/ml: 17/31 (55%) vs. 10/31 (32%); psa 1.01 < 2.0 ng/ml: 13/19 (68%) vs. 6/19 (32%);psa > 2.0: 50/57 (88%) vs. 39/57 (68%) 18fdcfpyl- 18f-fluoromethylcholine -pet/ct, respectively) . comparable results found phase iii trial 18f-psma-1007 versus 18f-fluorocholine pet/ct localisation prostate cancer biochemical recurrence. prospective, randomised, crossover multi-centre study, overall correct detection rates significantly higher 18f-psma-1007 18f-fluorocholine undetermined findings considered positive malignancy (0.82 vs. 0.65; p < 0.0001) . 6.4.4.1.6. whole-body axial mri whole body mri widely evaluated bcr limited value detection early metastatic involvement normal-sized lns . prospective series 68 patients bcr, diagnostic performance dw-mri significantly lower 68ga-psma pet/ct 18naf pet/ct diagnosing bone metastases . 6.4.4.2. assessment local recurrences 6.4.4.2.1. local recurrence radical prostatectomy sensitivity anastomotic biopsies low, especially psa levels < 1 ng/ml , srt usually decided basis bcr without histological proof local recurrence. dose delivered prostatic fossa tends uniform since demonstrated focal dose escalation site recurrence improves outcome. therefore, patients undergo srt without local imaging. magnetic resonance imaging detect local recurrences prostatic bed. psa threshold mri positivity seems 0.3 0.5 ng/ml; psa kinetics also influence mri positivity, even low psa values . two single-centre studies found negative mri independent predictor failure srt . conversely, small (≤0.4 cc) relapse located vesico-urethral anastomosis associated excellent prognosis salvage rt . prostate imaging recurrence reporting (pi-rr) system recently launched standardise mri interpretation context bcr rp rt . initial assessment suggests good reproducibility score . choline pet/ct less sensitive local relapse mri detects regional distant metastases . detection rates 68ga-psma pet/ct patients bcr rp increase psa level . psma pet/ct studies showed substantial part recurrences rp located outside prostatic fossa, even low psa levels . combining 68ga-psma pet mri may improve detection local recurrences, compared 68ga-psma pet/ct alone [945-947]. empire-1, single-centre, open-label, phase ii/iii rct included 365 patients detectable psa rp, negative results conventional imaging. randomised rt directed conventional imaging alone conventional imaging plus 18f-fluciclovine-pet/ct; patients m1 disease pet/ct group (n = 4) excluded patients cn1 irradiated pelvic nodes, without boost metastases. median follow-up 3.5 years, pet/ct group significantly associated longer event-free survival (hr: 2.04, 95% ci: 1.06–3.93, p = 0.0327) . 6.4.4.2.2. local recurrence radiation therapy patients bcr rt, biopsy status major predictor outcome, provided biopsies obtained 18–24 months initial treatment. given morbidity local salvage options necessary obtain histological proof local recurrence treating patient . mri yielded excellent results identifying local recurrence used biopsy targeting guiding local salvage treatment , even slightly underestimates volume local recurrence . prostate-specific membrane antigen pet/ct also detect local recurrences rt concordance psma pet/ct mri highly suggestive cancer recurrence . 6.4.4.3. summary evidence imaging case biochemical recurrence patients bcr imaging detect local recurrences distant metastases, however, sensitivity detection depends psa level. rp, psma pet/ct imaging modality highest sensitivity low psa levels (< 0.5 ng/ml) may help distinguishing patients recurrences confined prostatic fossa distant metastases may impact design use post-rp srt. rt, mri shown excellent results detecting local recurrences guiding prostate biopsy. given substantial morbidity post-rt local salvage treatments, distant metastases must ruled patients local recurrences fit salvage therapies. choline-,fluciclovine- psma-pet/ct used detect metastases patients indication psma pet/ct seems sensitive technique. 6.4.4.4. summary evidence guidelines imaging patients biochemical recurrence recommendationsstrength ratingprostate-specific antigen (psa) recurrence radical prostatectomyperform prostate-specific membrane antigen (psma) positron emission tomography/computed tomography (pet/ct) psa level > 0.2 ng/ml results influence subsequent treatment decisions (eau bcr risk groups).weakin case psma pet/ct available, psa level ≥ 1 ng/ml, perform fluciclovine pet/ct choline pet/ct imaging results influence subsequent treatment decisions.weakpsa recurrence radiotherapyperform prostate magnetic resonance imaging localise abnormal areas guide biopsies patients fit local salvage therapy.weakperform psma pet/ct (if available) fluciclovine pet/ct choline pet/ct patients fit curative salvage treatment.strong